Download PDF
Semin Musculoskelet Radiol 2002; 06(3): 191-196
DOI: 10.1055/s-2002-36716
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Oncogenic Osteomalacia

Kelli Andresen Edmister, Murali Sundaram
  • Department of Radiology, Mayo Clinic, Rochester, Minnesota
Further Information

Publication History

Publication Date:
23 January 2003 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Oncogenic osteomalacia is a rare paraneoplastic syndrome caused by bone and soft tissue tumors. The characteristic clinical, metabolic, and imaging findings are reviewed, as is the radiologist's role in evaluation and diagnosis. New insight into the pathophysiology of oncogenic osteomalacia is also presented.

KEYWORD

Oncogenic osteomalacia - metabolic bone disease - matrix extracellular phosphoglycoprotein - tumor imaging

REFERENCES

  • 1 Prader V A, Illig R, Vehlinger E, Stalder G. Rachitis, Infole, Knochen tumors.  Helv Pediatr Acta . 1959;  14 554-565
    PubMedGoogle Scholar
  • 2 Dorfman H D, Czerniak B. Bone Tumors.  St. Louis: Mosby 1998: 1111-1119
    Google Scholar
  • 3 Camus J P, Crouzet J, Prier A. Osteomalacies hypophosphoremiques guéries par l'ablation de tumeurs benignes du tisu conjonctif.  Ann Med Intern (Paris) . 1980;  131 422-426
    PubMedGoogle Scholar
  • 4 Furuya K, Isobe Y, Morita M. Hypertrophic osteoarthropathy and hypophosphatemic osteomalacia associated with tumor.  Gan To Kajaku Ryoho . 1986;  13 2056-2064
    PubMedGoogle Scholar
  • 5 Gitelis S, Ryan W J, Rosenberg A G, Templeton A C. Adult-onset hypophosphatemic osteomalacia secondary to vascular tumors of bone and soft tissue.  J Bone Joint Surg Am . 1986;  68 134-138
    PubMedGoogle Scholar
  • 6 McClure J, Smith P S. Oncogenic osteomalacia.  J Clin Pathol . 1987;  40 446-453
    PubMedGoogle Scholar
  • 7 Renton P, Shaw D G. Hypophosphatemic osteomalacia secondary to vascular tumors of bone and soft tissue.  Skeletal Radiol . 1976;  1 21-24
    CrossrefPubMedGoogle Scholar
  • 8 Seshadri M S, Cornish C J, Mason R S, Posen S. Parathyroid hormone-like bioactivity in tumors from patients with oncogenic osteomalacia.  Clin Endocrinol . 1985;  23 689-697
    PubMedGoogle Scholar
  • 9 Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors.  Cancer . 1987;  59 1442-1454
    CrossrefPubMedGoogle Scholar
  • 10 Pollack J A, Schiller A L, Crawford J D. Rickets and myopathy cured by removal of a non-ossifying fibroma of bone.  Pediatrics . 1973;  52 364-372
    PubMedGoogle Scholar
  • 11 Martini A, Notarangeleno L D, Barberis L. Acquired vitamin-D resistant rickets caused by prolonged latency in appearance of bone tumor.  Am J Dis Child . 1983;  137 1025-1026
    PubMedGoogle Scholar
  • 12 Sparagana M. Tumor-induced osteomalacia: long-term follow up of two patients cured by removal of their tumors.  J Surg Oncol . 1987;  36 198-205
    PubMedGoogle Scholar
  • 13 Nomura G, Koshino Y, Morimoto H. Vitamin D resistant hypophosphatemic osteomalacia associated with osteosarcoma of the mandible: report of a case.  Jpn J Med . 1981;  21 35-39
    PubMedGoogle Scholar
  • 14 Park Y K, Unni K K, Beabout J W, Hodgson S F. Oncogenic osteomalacia: a clinicopathologic study of 17 bone lesions.  J Korean Med Sci . 1994;  9 289-298
    PubMedGoogle Scholar
  • 15 Wyman A L, Paratinas F J, Daly J R. Hypophosphatemic osteomalacia associated with a malignant tumor of the tibia: report of a case.  J Clin Pathol . 1997;  30 328-335
    PubMedGoogle Scholar
  • 16 Sparagana M. Tumor-induced osteomalacia: long-term follow up of two patients cured by removal of their tumors.  J Surg Oncol . 1987;  36 198-205
    PubMedGoogle Scholar
  • 17 Castleman B, Mc Neely U B. Case records of the Massachusetts General Hospital.  N Engl J Med . 1965;  273 494-504
    PubMedGoogle Scholar
  • 18 Hasegawa T, Shimoda T, Yokoyama R. Intracortical osteoblastic osteosarcoma with oncogenic rickets.  Skeletal Radiol . 1999;  28 41-45
    CrossrefPubMedGoogle Scholar
  • 19 Clunie F PR, Fox P E, Stamp T CB. Four cases of acquired hypophosphatemic ("oncogenic") osteomalacia: problems of diagnosis, treatment and long-term management.  Rheumatology . 2000;  39 1415-1421
    CrossrefPubMedGoogle Scholar
  • 20 Seufert J, Ebert K, Muller J, Eulert. Brief report: octreotide therapy for tumor-induced osteomalacia.  N Engl J Med . 2001;  345 1883-1888
    CrossrefPubMedGoogle Scholar
  • 21 Ohashi K, Ohnishi T, Ishikawa T. Oncogenic osteomalacia presenting as bilateral stress fractures of the tibia.  Skeletal Radiol . 1999;  28 46-48
    CrossrefPubMedGoogle Scholar
  • 22 Avila N A, Skarulis M, Rubino D M, Doppman J L. Oncogenic osteomalacia: lesion detection by MR skeletal survey.  AJR Am J Roentgenol . 1996;  167 343-345
    PubMedGoogle Scholar
  • 23 Jan de Beur M S, Streeten E A, Civelek A C. Localisation of mesenchymal tumours by somatostatin receptor imaging [research letter].  Lancet . 2002;  359 761-763
    CrossrefPubMedGoogle Scholar
  • 24 Sundaram M, McCarthy E F. Oncogenic osteomalacia.  Skeletal Radiol . 2000;  29 117-124
    CrossrefPubMedGoogle Scholar
  • 25 Drezner M K. Tumor-induced rickets and ostomalacia. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism New York: Raven Press 1996: 319-325
    Google Scholar
  • 26 Aschinberg L C, Solomon L M, Zeis P M, Justice P, Rosenthal I M. Vitamin D-resistant rickets associated with epidermal nevus syndrome: demonstration of a phosphaturic substance in the dermal lesions.  J Pediatr . 1977;  91 56-60
    PubMedGoogle Scholar
  • 27 Lau K, Stom M C, Goldberg M. Evidence for a humoral phosphaturic factor in oncogenic hypophosphatemic osteomalacia (Abst).  Clin Res . 1979;  27 421
    PubMedGoogle Scholar
  • 28 Popvtzer M M. Tumor-induced hypophosphatemic osteomalacia (TUO): evidence for a phosphaturic cyclic AMP-independent action of tumor extract (Abst).  Clin Res . 1981;  29 418
    PubMedGoogle Scholar
  • 29 Miyauchi A, Fukase M, Tsutsumi M, Fujita T. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity.  J Clin Endocrinol Metab . 1988;  67 46-53
    PubMedGoogle Scholar
  • 30 Cai Q, Hodgson S F, Kao P C. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia.  N Engl J Med . 1994;  330 1645-1649
    CrossrefPubMedGoogle Scholar
  • 31 Econs M J, Drezner M K. Tumor-induced osteomalacia: unveiling a new hormone [editorial comment].  N Engl J Med . 1994;  330 1679-1681
    CrossrefPubMedGoogle Scholar
  • 32 Shimada T, Mizutani S, Muto T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.  Proc Natl Acad Sci USA . 2001;  98 6500-6505
    CrossrefPubMedGoogle Scholar
  • 33 John M R, Wickert H, Zaar K. A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma.  Bone . 2001;  29 393-402
    CrossrefPubMedGoogle Scholar
  • 34 Rowe P SN, de Zoysa A P, Dong R. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia.  Genomics . 2000;  67 54-68
    CrossrefPubMedGoogle Scholar
  • 35 Argiro L, Desbarats M, Glorieux F H, Ecarot B. MEPE, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.  Genomics . 2001;  74 342-351
    CrossrefPubMedGoogle Scholar
  • 36 Francis F, Henning S, Korn B. Positional cloning of PEX: a phosphate regulating gene with homologies to endopeptidases is detected in patients with X-linked hypophosphatemic rickets.  Nat Genet . 1995;  11 130-136
    PubMedGoogle Scholar
      >